Human Dopaminergic Progenitor Cells
Human Dopaminergic Progenitor Cells is a biological therapy with 5 clinical trials. Currently 4 active trials ongoing.
Success Metrics
Phase Distribution
Phase Distribution
4
Early Stage
1
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
0.0%
0 of 0 finished
0.0%
0 ended early
4
trials recruiting
5
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy
This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.
The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease
The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease
The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease
Clinical Trials (5)
A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy
This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.
The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease
The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease
The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5